REGN5381 / Regeneron 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
REGN5381 / Regeneron
2021-006337-19: A study to examine the safety, tolerability and biological effects of a single intravenous (IV) dose of REGN5381 or placebo in adult heart failure patients

Not yet recruiting
2
80
Europe
REGN5381, Lyophilisate for solution for infusion
Regeneron Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc.
New York Heart Association (NYHA) class II/III heart failure and LVEF <50%, Diseases associated with heart failure, Diseases [C] - Cardiovascular Diseases [C14]
 
 
NCT05353166: REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure

Recruiting
2
122
Europe, RoW
REGN5381, Matching Placebo
Regeneron Pharmaceuticals
Heart Failure
04/25
04/25
NATRIX-BNP, NCT06237309: REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction

Recruiting
2
391
Europe, RoW
REGN5381, Placebo
Regeneron Pharmaceuticals
Heart Failure
01/26
04/26
NCT05291546: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants

Completed
1
93
Europe
REGN9035, REGN5381, Placebo
Regeneron Pharmaceuticals
Healthy Volunteers
04/24
04/24

Download Options